Cookies are used to help provide a better web service to patients and others.
Uses include: remembering products you add to our cart, understanding what people need and ensuring our website works properly.
The dramatic before-and-after images show eight men's incredible response to cutting-edge treatment.
The study showed that the relative survival gain almost doubled in men, compared to female patients, regardless of the type of cancer and drugs given.
Researchers say the addition of Keytruda (pembrolizumab) in this study almost doubled the response rate of chemo for patients with NSCLC.
The FDA has approved a wearable device to treat withdrawal symptoms such as agitation, anxiety, depression, and opiate cravings.
The 52% (95% CI, 41-62) ORR included a complete response rate of 40% and a partial response rate of 12%.
The latest approval renders the previous 'temporary approval' a full approval, without further results needed.
Researchers believe these differences are due to a reduced immunosuppressive tumor environment in older patients.
It’s believed that this immunotherapy and its dual approach to fighting cancer will be a notable complement to existing immuno-oncology treatments.
The Food and Drug Administration (FDA) has drawn attention to efficacy issues associated with Keytruda or Tecentriq in some clinical trials - patients and healthcare professionals should take note.
Tagrisso (osimertinib) has been approved in Europe to treat Epidermal Growth Factor Receptor (EGFR) mutated non-small cell lung cancer (NSCLC) as a first-line treatment.